Gilead’s CAR T breakthrough: Yescarta delivers consistent results beyond transplant settings

How do ZUMA-7 and ALYCANTE data reinforce the case for Yescarta in second-line large B-cell lymphoma?

Kite, a Gilead Sciences company listed on the Nasdaq as GILD, has released a pivotal pooled analysis from the ZUMA-7 and ALYCANTE clinical trials that shows its CAR T-cell therapy Yescarta (axicabtagene ciloleucel) consistently delivers durable survival outcomes, even in patients who are ineligible for high-dose chemotherapy and stem cell transplant. The results were shared at the 67th American Society of Hematology Annual Meeting and Exposition in December 2025.

The analysis compared four-year data from the Phase 3 ZUMA-7 study with two-year outcomes from the Phase 2 ALYCANTE trial. While ZUMA-7 involved patients who were eligible for stem cell transplant, ALYCANTE focused on those who were not. This comprehensive evaluation offers compelling evidence that Yescarta can deliver high rates of complete response and prolonged survival across the spectrum of patients with relapsed or refractory large B-cell lymphoma, regardless of prior treatment eligibility.

This positions Yescarta as a frontrunner in the evolving second-line treatment landscape for large B-cell lymphoma. According to clinicians involved in the trial, the data set reinforces that CAR T-cell therapies such as Yescarta may be suitable for earlier use in the treatment continuum, particularly for populations previously considered too frail for aggressive options like autologous stem cell transplant.

What survival outcomes did Yescarta deliver in the combined trial population?

The pooled efficacy analysis included 178 patients from ZUMA-7 and 69 patients from ALYCANTE. Across the combined cohort, the two-year overall survival rate stood at 64.9 percent. This marks a significant improvement over the historical two-year survival rate for relapsed or refractory large B-cell lymphoma, which has hovered near 20 percent. Individually, ZUMA-7 reported a two-year survival of 62.8 percent while ALYCANTE saw a slightly higher rate at 70.8 percent, indicating encouraging outcomes even in transplant-ineligible patients.

Event-free survival at two years came in at 45.2 percent for the pooled population. ZUMA-7 and ALYCANTE showed near-identical EFS figures of 45.4 percent and 44.7 percent respectively. Similarly, progression-free survival across the combined dataset reached 47.4 percent, with minimal deviation between the two trials.

At three months post-treatment, 55.6 percent of all patients had achieved a complete metabolic response. This figure rose to 67.7 percent among ALYCANTE participants and was 51.2 percent in the ZUMA-7 arm. The overall response rate one year post-treatment remained consistent at around 46 percent for both cohorts. Among those who achieved a response, 61 percent maintained it through the first year, highlighting the durability of remission.

These results collectively demonstrate that Yescarta is not only effective but also exhibits long-lasting treatment responses in a setting where previous therapeutic options have often resulted in short-term benefits.

How do the safety outcomes compare between the two trial populations?

The safety analysis included 232 patients treated with Yescarta across both trials, comprising 170 from ZUMA-7 and 62 from ALYCANTE. Grade 3 or higher treatment-emergent adverse events were reported in 90.5 percent of patients across the pooled cohort. ZUMA-7 had a slightly higher incidence at 91.2 percent compared to 88.7 percent in ALYCANTE.

Among notable side effects, severe neurologic events occurred in 19.8 percent of the pooled patients. In ZUMA-7, this rate was 21.2 percent, while ALYCANTE recorded a lower incidence at 16.1 percent. Neutropenia occurred in 64.7 percent of all cases, with 70 percent incidence in ZUMA-7 and 50 percent in ALYCANTE. Anemia was observed in 27.6 percent overall, again slightly higher in ZUMA-7.

Importantly, patient-reported outcomes related to quality of life offered additional reassurance. Although patients experienced an initial decline in physical function and global health scores post-treatment, these effects were transient. ALYCANTE patients reported meaningful quality of life improvements by Day 100, and ZUMA-7 participants reached similar levels by Day 150. Both groups showed sustained improvement through two years.

Why is this data significant for patients ineligible for stem cell transplant?

Professor Roch Houot, who led the ALYCANTE study at the University Hospital of Rennes, emphasized that patients who cannot undergo stem cell transplantation typically face limited options and poor prognosis. Many are excluded due to age, comorbid conditions, or reduced performance status. The ALYCANTE data demonstrates that even this population can derive robust and durable benefit from Yescarta as a second-line treatment, supporting earlier integration into care pathways.

This development holds major implications for clinical practice. Previously, patients ineligible for transplant had few curative options, and treatment often focused on palliation. Yescarta now offers a viable curative-intent therapy for this group, signaling a shift in how hematologists may approach treatment planning in the near future.

What is the current regulatory and commercial status of Yescarta?

Yescarta was approved in the United States in April 2022 for the treatment of relapsed or refractory large B-cell lymphoma within 12 months of first-line therapy, based on data from ZUMA-7. The European Union followed with an approval in October 2022, with additional regulatory green lights issued in countries including Canada, Japan, Australia, Israel, Switzerland, and the United Kingdom.

ZUMA-7 is the largest global randomized study comparing CAR T-cell therapy against standard platinum-based chemotherapy followed by transplant. Its results were pivotal in gaining wide regulatory acceptance for Yescarta as a second-line treatment.

ALYCANTE, sponsored by LYSA and managed by LYSARC, complements ZUMA-7 by targeting an underserved patient segment and reinforcing the broader applicability of Yescarta. Both studies continue to influence clinical guidelines and insurance coverage frameworks.

How is Gilead Sciences positioning Yescarta in its oncology strategy?

Kite and Gilead Sciences are doubling down on cell therapy as a strategic growth driver. Gallia Levy, Kite’s Global Head of Development, described the pooled analysis as reinforcing the therapy’s curative potential across a broader patient base. The data adds further weight to Yescarta’s position in the market, especially as Gilead expands its oncology pipeline with other modalities like antibody-drug conjugates and small molecules.

Institutional analysts believe the long duration of response and the ability to treat difficult-to-manage patient groups add significant commercial value to Yescarta. Investors are watching closely for signs that CAR T-cell therapies could move even earlier in treatment paradigms, perhaps into frontline settings pending future trial outcomes.

What ongoing safety considerations should physicians and patients be aware of?

Yescarta carries boxed warnings for cytokine release syndrome and neurologic toxicities. In ZUMA-7, cytokine release syndrome occurred in 93 percent of patients, with 9 percent experiencing Grade 3 or higher severity. Neurologic toxicities affected 74 percent of patients, with a similar rate of serious outcomes.

While most adverse effects are manageable and occur within the first few weeks post-infusion, the product label emphasizes the need for monitoring, supportive care, and access to treatments like tocilizumab. Secondary concerns such as prolonged cytopenias, infections, and rare secondary malignancies remain, but are manageable with appropriate protocols.

Gilead and Kite continue to refine management strategies, including prophylactic corticosteroid use and pre-treatment screening, to reduce the incidence and severity of adverse events without compromising efficacy.

What are the key takeaways from the ZUMA-7 and ALYCANTE Yescarta analysis?

• Yescarta achieved a two-year overall survival rate of 64.9 percent across both ZUMA-7 and ALYCANTE trials

• Complete metabolic response was observed in more than half of patients, including 67.7 percent in the ALYCANTE cohort

• Event-free and progression-free survival rates exceeded 45 percent in both transplant-eligible and ineligible groups

• Quality of life improvements were sustained through two years, supporting patient-centric outcomes

• Safety profile was consistent with prior data, with manageable rates of CRS and neurologic toxicity

• Regulatory approvals in the United States, EU, Japan, and other key markets have broadened global adoption

• Yescarta’s second-line positioning is expected to expand further into transplant-ineligible populations

• Gilead Sciences is leveraging Kite Oncology to anchor its cell therapy growth strategy

• Analysts believe Yescarta’s long-term durability and broad utility strengthen its competitive moat

• Continued readouts from ongoing trials may support future label expansions or earlier-line usage